This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
DNA methylation markers in the diagnosis and prognosis of common leukemias
Signal Transduction and Targeted Therapy Open Access 10 January 2020
-
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
Blood Cancer Journal Open Access 30 June 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kuriakose P . Targeted therapy for hematologic malignancies. Cancer Control 2005; 12: 82–90.
Ferreri AJ, Dognini GP, Verona C, Patriarca C, Doglioni C, Ponzoni M . Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma. Haematologica 2007; 92: e1–e2.
Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a children'soncology group pilot study. J Clin Oncol 2008; 26: 3756–3762.
Chevallier P, Mahe B, Garand R, Talmant P, Harousseau JL, Delaunay J . Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukaemia patient harbouring CD33 expression. Int J Hematol 2008; l88: 209–211.
Laporte JP, Isnard F, Garderet L, Fouillard L, Gorin NC . Remission of adult acute lymphocytic leukaemia with alemtuzumab. Leukemia 2004; 18: 1557–1558.
Chevallier P, Robillard N, Wuilleme-Toumi S, Mechinaud F, Harousseau JL, Avet-Loiseau H . Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukaemia patients and is associated with chemoresistance in these patients. Haematologica 2004; 89: 1399–1401.
Zent CS, Call TG, Shanafelt TD, Tschumper RC, Jelinek DF, Bowen DA et al. Early treatment of high-risk chronic lymphoblastic leukaemia with alemtuzumab and rituximab. Cancer 2008; 113: 2110–2118.
Chevallier P, Robillard N, Ayari S, Guillaume T, Delaunay J, Mechinaud F et al. Persistence of CD33 expression at relapse in CD33+ AML patients after receiving gemtuzumab in the course of the disease. Br J Haematol 2008, (in press) DOI:10.1111/j.1365-2141.2008-07153.x.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chevallier, P., Robillard, N., Houille, G. et al. Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases. Leukemia 23, 806–807 (2009). https://doi.org/10.1038/leu.2008.303
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.303
This article is cited by
-
Advances in Supportive Care for Acute Lymphoblastic Leukemia
Current Hematologic Malignancy Reports (2020)
-
DNA methylation markers in the diagnosis and prognosis of common leukemias
Signal Transduction and Targeted Therapy (2020)
-
Mechanisms of resistance to CAR T cell therapy
Nature Reviews Clinical Oncology (2019)
-
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Nature Medicine (2018)
-
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
Blood Cancer Journal (2017)